Create a narrative

Ascentage Pharma Group International Community

SEHK:6855 Community

1 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

Ascentage Pharma Group International

AN

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

Takeda Deal And Olverembatinib Trials Will Open Global Markets

Key Takeaways Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth. Successful NASDAQ IPO and promising registrational trials position the company to accelerate pipeline development, enhancing future earnings potential.

HK$55.14

FV

15.8% undervalued

20.82%

Revenue growth p.a.

0

0

0

7 days ago